IBIO
Price
$1.13
Change
+$0.01 (+0.90%)
Updated
Oct 2 closing price
Capitalization
75.24M
44 days until earnings call
Intraday BUY SELL Signals
NUVB
Price
$5.14
Change
-$0.42 (-7.55%)
Updated
Oct 2 closing price
Capitalization
1.97B
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBIO vs NUVB

IBIO vs NUVB Comparison Chart in %
View a ticker or compare two or three
VS
IBIO vs. NUVB commentary
Oct 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and NUVB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
IBIO vs NUVB: Fundamental Ratings
IBIO
NUVB
OUTLOOK RATING
1..100
5053
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a15

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NUVB's Valuation (47) in the null industry is in the same range as IBIO (74) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.

NUVB's Profit vs Risk Rating (100) in the null industry is in the same range as IBIO (100) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.

NUVB's SMR Rating (98) in the null industry is in the same range as IBIO (98) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.

NUVB's Price Growth Rating (59) in the null industry is in the same range as IBIO (64) in the Biotechnology industry. This means that NUVB’s stock grew similarly to IBIO’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as NUVB (100) in the null industry. This means that IBIO’s stock grew similarly to NUVB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIONUVB
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 17 days ago
83%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Oct 04, 2026
Stock price -- (IBIO: $1.13 vs. NUVB: $5.14)
Brand notoriety: IBIO and NUVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 103% vs. NUVB: 277%
Market capitalization -- IBIO: $75.24M vs. NUVB: $1.97B
IBIO [@Biotechnology] is valued at $75.24M. NUVB’s [@Biotechnology] market capitalization is $1.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 0 FA rating(s) are green while NUVB’s FA Score has 0 green FA rating(s).

  • IBIO’s FA Score: 0 green, 5 red.
  • NUVB’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVB is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 4 TA indicator(s) are bullish while NUVB’s TA Score has 4 bullish TA indicator(s).

  • IBIO’s TA Score: 4 bullish, 4 bearish.
  • NUVB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IBIO is a better buy in the short-term than NUVB.

Price Growth

IBIO (@Biotechnology) experienced а -5.46% price change this week, while NUVB (@Biotechnology) price change was -10.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

IBIO is expected to report earnings on Nov 17, 2026.

NUVB is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IBIO
Daily Signal:
Gain/Loss:
NUVB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QQQS42.880.43
+1.01%
Invesco NASDAQ Future Gen 200 ETF (QQQS)
NCA8.420.02
+0.24%
Nuveen California Municipal Value Fund
HODL23.84-0.08
-0.33%
VanEck Bitcoin ETF (HODL)
SZK22.46-0.11
-0.50%
ProShares UltraShort Consumer Staples (SZK)
LINT157.91-2.09
-1.30%
Direxion Daily INTC Bull 2X ETF (LINT)

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
+1.35%
WVE - IBIO
47%
Loosely correlated
-2.58%
REPL - IBIO
38%
Loosely correlated
-2.83%
NUVB - IBIO
34%
Loosely correlated
-7.55%
GPCR - IBIO
33%
Loosely correlated
-4.52%
ADMA - IBIO
31%
Poorly correlated
-2.11%
More

NUVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with SVRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVB
1D Price
Change %
NUVB100%
-7.55%
SVRA - NUVB
45%
Loosely correlated
-4.66%
FDMT - NUVB
41%
Loosely correlated
-1.23%
VCYT - NUVB
40%
Loosely correlated
+3.67%
ANNX - NUVB
39%
Loosely correlated
+1.70%
RAPP - NUVB
38%
Loosely correlated
-2.01%
More